PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(06): 666-678
DOI: 10.1055/a-1471-4063
GebFra Science
Review/Übersicht

Neue Therapiestrategien beim HER2-positiven fortgeschrittenen, inoperablen bzw. metastasierten Mammakarzinom

Artikel in mehreren Sprachen: English | deutsch
Diana Lüftner
1   Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité, Universitätsmedizin Berlin, Berlin, Germany
,
Matthias Peipp
2   Sektion für Stammzelltransplantation und Immuntherapie, Dr. Mildred-Scheel-Haus, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Trotz therapeutischer Fortschritte bei der Behandlung des HER2-positiven (HER2: humaner epidermaler Wachstumsfaktor-Rezeptor 2) fortgeschrittenen/metastasierten Mammakarzinoms besteht weiterhin ein dringender Bedarf an wirksameren Therapieoptionen. Jenseits der zweiten Therapielinie gibt es derzeit keinen definierten, zugelassenen Therapiestandard. Eine der großen Herausforderungen ist die Überwindung von Therapieresistenzen. In Abhängigkeit vom zugrunde liegenden Resistenzmechanismus werden verschiedene Strategien für neue innovative Therapiekonzepte beim HER2-positiven Mammakarzinom verfolgt. Ein wichtiger Fokus liegt dabei auf spezifisch designten Antikörpern für eine gezielte Therapie, um diesen Herausforderungen erfolgreich zu begegnen. Mit Trastuzumab-Deruxtecan (T-DXd, DS-8201a) befindet sich ein optimiertes Antikörper-Wirkstoff-Konjugat (ADC: Antibody Drug Conjugate) in der klinischen Prüfung, das vielversprechende Studienergebnisse bei bereits intensiv vorbehandelten Patienten mit fortgeschrittenem, inoperablem oder metastasiertem, HER2-positivem Mammakarzinom zeigt. Aufgrund dieser Datenlage ist T-DXd in den USA und Japan bereits für das HER2-positive fortgeschrittene, inoperable bzw. metastasierte Mammakarzinom zugelassen – in den USA nach mindestens 2 vorangegangenen anti-HER2 zielgerichteten Therapielinien und in Japan nach vorangegangener Chemotherapie. T-DXd steht stellvertretend für ein erfolgreiches „Antikörper-Engineering“. Seit Anfang des Jahres ist T-DXd auch in Europa als Monotherapie beim inoperablen oder metastasierten HER2-positiven Mammakarzinom zugelassen bei Patienten, die mindestens 2 gegen HER2 gerichtete Vorbehandlungen erhalten haben. In der vorliegenden Publikation werden Strategien zur Verbesserung von Therapieoptionen beim HER2-positiven fortgeschrittenen, inoperablen bzw. metastasierten Mammakarzinom vorgestellt – unter anderem am Beispiel der Entwicklung von T-DXd.

Schlüsselwörter

metastasiertes HER2-positives Mammakarzinom - HER2-gerichtete Therapieoptionen - Antikörper - Antikörper-Wirkstoff-Konjugat - T-DXd - DS-8201


Publikationsverlauf

Eingereicht: 20. Dezember 2020

Angenommen: 27. März 2021

Artikel online veröffentlicht:
21. Juni 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 American Cancer Society. Breast Cancer HER2 Status. Page 27–29. Accessed November 19, 2020 at: https://www.cancer.org/content/dam/CRC/PDF/Public/8580.00.pdf
    PubMedGoogle Scholar
  • 2 American Cancer Society. Treating Breast Cancer 2019. Targeted therapy for HER2-positive breast cancer. Page 56. Accessed April 25, 2020 at: https://www.cancer.org/content/dam/CRC/PDF/Public/8581.00.pdf
    PubMedGoogle Scholar
  • 3 Giordano SH, Temin S, Chandarlapaty S. et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical update. J Clin Oncol 2018; 36: 2736-2740
    CrossrefPubMedGoogle Scholar
  • 4 Denduluri N, Chavez-MacGregor M, Telli ML. et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 2018; 36: 2433-2443
    CrossrefPubMedGoogle Scholar
  • 5 Thill M, Friedrich M, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer (MBC): Update 2021. Breast Care 2021; DOI: 10.1159/00051620.
    CrossrefPubMedGoogle Scholar
  • 6 Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 4.3 – Februar 2020. AWMF-Registernummer: 032–045OL. Accessed April 26, 2020 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
    PubMedGoogle Scholar
  • 7 Piccart M, Procter M, Fumagalli D. et al. Interim Overall Survival Analysis of APHINITY. A randomised multi-center, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus Pertuzumab versus chemotherapy plus Trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019, San Antonio/Texas/USA, Dezember 2019. Oral presentation GS1-4.
    PubMedGoogle Scholar
  • 8 Geyer CE, Huang C-S, Mano MS. et al. Phase III Study of Trastuzumab Emtansine (T-DM1) vs. Trastuzumab as Adjuvant Therapy in Patients with HER2-positive Early Breast Cancer with Residual Invasive disease after Neoadjuvant Chemotherapy and HER2-Targeted Therapy Including Trastuzumab: Primary Results from KATHERINE. SABCS 2018. San Antonio/Texas/USA, Dezember 2018. Oral presentation GS1-10.
    PubMedGoogle Scholar
  • 9 Verniere C, Milano M, Brambilla M. et al. Resistance Mechanisms to anti-HER2 Therapies in HER2-positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives. Crit Rev Oncol Hematol 2019; 139: 53-66 DOI: 10.1016/j.critrevonc.2019.05.001.
    CrossrefPubMedGoogle Scholar
  • 10 Larionov AA. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Front Oncol 2018; 8: 89 DOI: 10.3389/fonc.2018.00089.
    CrossrefPubMedGoogle Scholar
  • 11 Veeraraghavan J, De Angelis CD, Reis-Filho JS. et al. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 2017; 34 (Suppl. 01) S19-S26 DOI: 10.1016/j.breast.2017.06.022.
    CrossrefPubMedGoogle Scholar
  • 12 Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019; 11: 1-16 DOI: 10.1177/1758835919833519.
    CrossrefPubMedGoogle Scholar
  • 13 Murthy RK, Loi S, Okines A. et al. Tucatinib, trastuzumab and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020; 382: 597-609 DOI: 10.1056/NEJMoa1914609.
    CrossrefPubMedGoogle Scholar
  • 14 Lin NU, Borges V, Anders C. et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capectabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol ASCO 2020; #1005 Accessed November 26, 2020 at: http://ascopubs.org/doi/abs/10.1200/JCO.20.00775
    CrossrefPubMedGoogle Scholar
  • 15 Accessed May 22, 2021 at: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020
    PubMed
  • 16 Accessed May 22, 2021 at: https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_de.pdf
    PubMed
  • 17 Collins DM, Conlon NT, Kannan S. et al. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers 2019; 11: 737 DOI: 10.3390/cancers11060737.
    CrossrefPubMedGoogle Scholar
  • 18 Saura C, Oliveira M, Feng YH. et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol 2019; DOI: 10.1200/JCO.2019.37.15:suppl.1002.
    CrossrefPubMedGoogle Scholar
  • 19 Cocco E, Carmona FJ, Razavi P. et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Sci Signal 2019; DOI: 10.1126/scisignal.aa9773.
    CrossrefPubMedGoogle Scholar
  • 20 Smyth LM, Piha-Paul SA, Saura C. et al. Neratinib + fulvestrant for HER-mutant HR-positive metastatic breast cancer: Updated results from the phase 2 SUMMIT trial. San Antonio Breast Cancer Symposium 2018; PD3-06 DOI: 10.1158/1538-7445.SABCS18-PD3-06.
    CrossrefPubMedGoogle Scholar
  • 21 Shah M, Nunes MR, Stearns V. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer?. Oncology 2018; 32: 216-222
    PubMedGoogle Scholar
  • 22 Scott SC, Lee S, Abraham J. Mechanisms of Therapeutic CDK4/6 Inhibition in Breast Cancer. Semin Oncol 2017; 44: 385-394 DOI: 10.1053/j.seminoncol.2018.01.006.
    CrossrefPubMedGoogle Scholar
  • 23 Goel S, Wang Q, Watt AC. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 2016; 29: 255-269 DOI: 10.1016/j.ccell.2016.02.006.
    CrossrefPubMedGoogle Scholar
  • 24 Schedin TB, Borges VF, Shagisultanova E. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. Int J Breast Cancer 2018; 2018: 7835095 DOI: 10.1155/2018/7835095.
    CrossrefPubMedGoogle Scholar
  • 25 Tolaney SM, Wardley AM, Zambelli S. et al. MonarcHER: a randomized phase 2 study of abemaciclib plus trastuzumab with or without abemaciclib versus trastuzumab plus chemotherapy in women with HR+, HER2+ advanced breast cancer. Ann Oncol 2019; 30 (Suppl. 05) v851-v934 DOI: 10.1093/annonc/mdz394.
    CrossrefPubMedGoogle Scholar
  • 26 Tang J, Kong D, Cui Q. et al. Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis. Front Oncol 2018; 8: 374 DOI: 10.3389/fonc.2018.00374.
    CrossrefPubMedGoogle Scholar
  • 27 Yu S, Liu Q, Han X. et al. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol 2017; 6: 31 DOI: 10.1186/s40164-017-0091-4.
    CrossrefPubMedGoogle Scholar
  • 28 Clark MR. IgG effector mechanisms. Chem Immunol 1997; 65: 88-110
    CrossrefPubMedGoogle Scholar
  • 29 Musolino A, Naldi N, Bortesi B. et al. Immunglobulin G fragment C receptor polymorphismus and clinical efficacy of trastuzumab-based therapy in patients with HER1/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796
    CrossrefPubMedGoogle Scholar
  • 30 Gavin PG, Song N, Kim SR. et al. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol 2017; 3: 335-341
    CrossrefPubMedGoogle Scholar
  • 31 Rugo HS, Im SA, Cardoso F. et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. San Antonio Breast Cancer Symposium 2019. AACR Cancer Res 2020; 80 (4 Suppl.): Abstract GS1-02
    CrossrefPubMedGoogle Scholar
  • 32 Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944 DOI: 10.1158/0008-5472.CAN-09.0547.
    CrossrefPubMedGoogle Scholar
  • 33 Accessed November 26, 2020 at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available
    PubMed
  • 34 ENHERTU® for intravenous drip infusion 100 mg. Japan Prescibing Information. April 28, 2020.
    PubMedGoogle Scholar
  • 35 Accessed May 22, 2021 at: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_de.pdf
    PubMed
  • 36 Ogitani Y, Aida T, Hagihara K. et al. DS-8201a, A Novel HER2-targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res 2016; 22: 5097-5108
    CrossrefPubMedGoogle Scholar
  • 37 Ogitani Y, Hagihara K, Oitata M. et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016; 107: 1039-1046
    CrossrefPubMedGoogle Scholar
  • 38 Deng S, Lin Z, Li W. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment. Curr Med Chemistry 2017; 24: 1-23 DOI: 10.2174/0929867324666170530092350.
    CrossrefPubMedGoogle Scholar
  • 39 Beck A, Goetsch L, Dumontet C. et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews 2017; 16: 315-335 DOI: 10.1038/nrd.2016.268.
    CrossrefPubMedGoogle Scholar
  • 40 Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and divers approaches in ADC design. Pharmacol Ther 2018; 181: 126-142
    CrossrefPubMedGoogle Scholar
  • 41 Nakada T, Sugihara K, Jikoh T. et al. The Latest Research and Development into the Antibody-Drug-Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a). for HER2 Cancer Therapy. Chem Pharm Bull 2019; 67: 173-185
    CrossrefPubMedGoogle Scholar
  • 42 de Goeij. Peipp M, de Haij S. et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signalling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. Mabs 2014; 6: 392-402
    CrossrefPubMedGoogle Scholar
  • 43 Gramatzki M, Peipp M. Chapter 7: Fc Engineering. In: Dübel S, Reichert JM. eds. Handbook of Therapeutic Antibodies. Part 1. Wiley-VCH Verlag GmbH+CoKGaA; 2014: 141-170
    Google Scholar
  • 44 Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018; 9: 33-46 DOI: 10.1007/s13238-016-0323-0.
    CrossrefPubMedGoogle Scholar
  • 45 Mitsui I, Kumazawa E, Hirota Y. et al. A New Water-soluble Camptothecin Derivative, DX-8951 f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776-782
    CrossrefPubMedGoogle Scholar
  • 46 Doi T, Shitara K, Naito Y. et al. Safety, pharmacokinetics and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastrooesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 2017; 18: 1512-1522
    CrossrefPubMedGoogle Scholar
  • 47 Nagai Y, Oitate M, Shiozawa H. et al. Comprehensive Preclinical Pharmacokinetic Evaluations of Trastuzumab Deruxtecan (DS-8201a), a HER2-atrgeting antibody-drug conjugate, in Cynomolgus Monkeys. Xenobiotica 2019; 49: 1086-1096 DOI: 10.1080/00498254.2018.1531158.
    CrossrefPubMedGoogle Scholar
  • 48 Iwata H, Tamura K, Doi T. et al. Trastuzumab Deruxtecan in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. JCO ASCO 2018; 36 (Suppl. 15) 2501a
    CrossrefPubMedGoogle Scholar
  • 49 Poon KA, Flagella K, Beyer J. et al. Preclinical Safety Profile of Trastuzumab Emtansine: Mechanism of Action of Its Cytotoxic Component Retained With Improved Tolerability. Toxicol Appl Pharmacol 2013; 273: 298-313
    CrossrefPubMedGoogle Scholar
  • 50 Giuliani S, Ciniselli CM, Leonardi E. et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER23+ and HER22+/HER2 amplified cases. Virchows Arch 2016; 469: 45-50
    CrossrefPubMedGoogle Scholar
  • 51 Lal P, Salazar PA, Hudis CA. et al. HER2-testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparisons of dual-color an single-color scoring. Am J Clin Pathol 2004; 121: 631-636
    CrossrefPubMedGoogle Scholar
  • 52 Schalper KA, Kumar S, Hui P. et al. A retrospective population-based comparison of HER2 immunhistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med 2014; 138: 213-219
    CrossrefPubMedGoogle Scholar
  • 53 Tamura K, Shitara K, Naito Y. et al. Single Agent Activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. ESMO 2016. Ann Oncol 2016; 27: 1-36 LBA 17
    CrossrefPubMedGoogle Scholar
  • 54 Metzger-Filho O, Viale G, Trippa L. et al. HER2 heterogeneity as apredictor of response to neoadjuvant T-DM1 plus Pertuzumab: Results from a prospective clinical trial. ASCO 2019. J Clin Oncol 2019; 37 (Suppl. 15) 502a
    CrossrefPubMedGoogle Scholar
  • 55 Lee HE, Park KU, Yoo SB. et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49: 1448-1457
    CrossrefPubMedGoogle Scholar
  • 56 Shitara K, Bang YJ, Sugimoto N. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 2020; 382: 2419-2430 DOI: 10.1056/NEJMoa2004413.
    CrossrefPubMedGoogle Scholar
  • 57 Accessed April 28, 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf
    PubMed
  • 58 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
    CrossrefPubMedGoogle Scholar
  • 59 Tamura K, Tsurutani J, Takahashi S. et al. Trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 2019; 20: 816-826
    CrossrefPubMedGoogle Scholar
  • 60 Modi S, Park H, Murthy RK. et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol 2020; DOI: 10.1200/JCO.19.02318.
    CrossrefPubMedGoogle Scholar
  • 61 Krop I, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: DESTINY-Breast01 Study. SABCS 2019, San Antonio/Texas, USA, Dezember 2019, oral presentation GS1-03.
    PubMedGoogle Scholar
  • 62 Modi S, Saura C, Yamashita T. et al. Updated Results From DESTINY-Breast01, a Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Breast Cancer. SABCS 2020, Poster-Präsentation PD3-06.
    PubMedGoogle Scholar
  • 63 Accessed November 26, 2020 at: http://www.clinicaltrials.gov
    PubMed
  • 64 Jerusalem G, Park YH, Yamashita T. et al. CNS Metastases in HER2-Positive Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan: DESTINY-Breast01 Subgroup Analyses. European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting, May 2020. #1380.
    PubMedGoogle Scholar
  • 65 Iwata TN, Ishii C, Ishida A. et al. A HER2-Targeting Antibody-Drug-Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther 2018; 17: 1494-1503
    CrossrefPubMedGoogle Scholar